SCHEMBL5111271

SCHEMBL5111271

COC1Oc2c(c(=O)oc3c(C)cc(C)cc23)C1c1c(O)c2cc(C)cc(C)c2oc1=O

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 12/20 0.36
CSNK2B P67870 12/20 0.36
CSNK2A1 P68400 12/20 0.36
ESR1 P03372 2/20 0.35
ESR2 Q92731 2/20 0.35
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
MCL1 Q07820 1/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31
CA13 Q8N1Q1 1/20 0.31
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5343002 0.84 CSNK2A2 (0.38) CSNK2A2CSNK2BCSNK2A1ESR1ESR2
SCHEMBL5112371 0.81 ESR2 (0.36) ESR2MCL1
SCHEMBL5119347 0.81 CSNK2A2 (0.39) CSNK2A2CSNK2BCSNK2A1ALDH1A1MAPT
SCHEMBL5111577 0.81 NQO1 (0.47) CSNK2A2CSNK2BCSNK2A1ESR1ESR2
SCHEMBL5112451 0.79 NQO1 (0.48) CSNK2A2CSNK2BCSNK2A1ESR1ESR2
SCHEMBL5126126 0.79 NQO1 (0.48) CSNK2A2CSNK2BCSNK2A1ALDH1A1SMN1; SMN2
SCHEMBL5117858 0.79 NQO1 (0.46) CSNK2A2CSNK2BCSNK2A1ALDH1A1SMN1; SMN2
SCHEMBL6365692 0.77 PKLR (0.43) ESR1ESR2ALDH1A1SMN1; SMN2TP53
SCHEMBL5125433 0.77 NQO1 (0.38) CSNK2A2CSNK2BCSNK2A1ESR1ESR2
SCHEMBL5118604 0.77 ESR2 (0.46) ESR1ESR2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed
EP-1648902-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP disclosed
WO-2005010007-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA- ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action CYP11B2, CYP11B1, LTC4S CSNK2A2 886/4885CSNK2B 767/4885CSNK2A1 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.